Home › Funds › BlackBarn Capital Partners LP › AMRX

BlackBarn Capital Partners LP position in AMRX

AMNEAL PHARMACEUTICALS INC · Health Care

BlackBarn Capital Partners LP reported holding 1,300,000 shares of AMRX (AMNEAL PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$22.5M, representing 2.07% of its reported portfolio and ranking #12 among its reported holdings. BlackBarn Capital Partners LP has disclosed AMRX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)1.30M sh
Reported value held$22.50M
Portfolio Weight2.07%
First reportedQ1 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BlackBarn Capital Partners LP's AMRX position evolved

BlackBarn Capital Partners LP first disclosed a stake in AMRX in Q1 2024 at 1,413,297 shares (US$8.6M). The position peaked in Q2 2025 at 3,446,570 shares, worth US$27.9M. Across 10 filings, BlackBarn Capital Partners LP increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,300,000 shares valued at US$22.5M — a reduction of -350,000 shares quarter over quarter.. Notable position changes include a 42% increase in Q2 2024 (shares rose 31% over the following quarter), a 36% trim in Q3 2025 (shares rose 26% over the following quarter), a 28% trim in Q4 2025 (shares fell 1% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 1.41M $8.56M New
Q2 2024 2.00M $12.70M Add
Q3 2024 2.41M $20.06M Add
Q4 2024 2.85M $22.57M Add
Q1 2025 2.88M $24.15M Add
Q2 2025 3.45M $27.88M Add
Q3 2025 2.19M $21.92M Reduce
Q4 2025 1.57M $19.78M Reduce
Q1 2026 1.65M $20.51M Add
Q2 2026 1.30M $22.50M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AMRX and 13F data

AMRX (AMNEAL PHARMACEUTICALS INC) is a Health Care company. 47 other funds we track also report a position in AMRX — the largest reported positions include TPG GP A, LLC (US$213.4M), Rubric Capital Management LP (US$176.0M), Nantahala Capital Management, LLC (US$39.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AMRX

All AMRX fund holders →

FAQ

How long has BlackBarn Capital Partners LP held AMRX?

BlackBarn Capital Partners LP has disclosed AMRX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is BlackBarn Capital Partners LP's current position in AMRX?

As of Q2 2026, BlackBarn Capital Partners LP holds 1.30M shares of AMRX (AMNEAL PHARMACEUTICALS INC), valued at $22.50M, representing 2.07% of its reported portfolio and ranking #12.

Has BlackBarn Capital Partners LP been buying or selling AMRX?

In the latest 13F filing (Q2 2026), BlackBarn Capital Partners LP reduced its position in AMRX. The position peaked in Q2 2025 at 3.45M shares.

Which other funds hold AMRX?

Other major institutional holders of AMRX include TPG GP A, LLC, Rubric Capital Management LP, Nantahala Capital Management, LLC, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.